{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=emtricitabine%2Ftenofovir+disoproxil+fumarate+%28FTC%2FTDF%29&page=10", "query": { "intervention": "emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 234, "total_pages": 24, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=emtricitabine%2Ftenofovir+disoproxil+fumarate+%28FTC%2FTDF%29&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=emtricitabine%2Ftenofovir+disoproxil+fumarate+%28FTC%2FTDF%29&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T01:24:56.596Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00055120", "title": "When to Start Anti-HIV Drugs in Patients With Opportunistic Infections", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections", "AIDS-Related Opportunistic Infections" ], "interventions": [ { "name": "Emtricitabine/tenofovir disoproxil fumarate", "type": "DRUG" }, { "name": "Lopinavir/ritonavir", "type": "DRUG" }, { "name": "Stavudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 283, "start_date": "2003-03", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2014-10-15", "last_synced_at": "2026-10-14T01:24:56.596Z", "location_count": 43, "location_summary": "Sacramento, California • San Diego, California • San Francisco, California + 24 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00055120" }, { "nct_id": "NCT00344760", "title": "A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Enfuvirtide", "type": "DRUG" }, { "name": "Efavirenz, lamivudine, and tenofovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 2, "start_date": "2005-01", "completion_date": "2007-03", "has_results": false, "last_update_posted_date": "2021-05-11", "last_synced_at": "2026-10-14T01:24:56.596Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00344760" }, { "nct_id": "NCT01632995", "title": "Assessment of Pre-Exposure Prophylaxis (PrEP) Administered at Sexually Transmitted Disease (STD) Clinics", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "FTC 200 mg/TDF 300 mg fixed-dose combination tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 557, "start_date": "2012-10", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2021-11-05", "last_synced_at": "2026-10-14T01:24:56.596Z", "location_count": 3, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Miami, Florida", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01632995" }, { "nct_id": "NCT00851799", "title": "Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "Emtricitabine/tenofovir disoproxil fumarate", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Atazanavir", "type": "DRUG" }, { "name": "Raltegravir", "type": "DRUG" }, { "name": "Darunavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 334, "start_date": "2009-06", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2016-01-13", "last_synced_at": "2026-10-14T01:24:56.596Z", "location_count": 26, "location_summary": "Los Angeles, California • San Francisco, California • Torrance, California + 18 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00851799" }, { "nct_id": "NCT01326221", "title": "Single Dose Truvada in HIV-negative Men and Women", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pharmacokinetic Study in Healthy Volunteers" ], "interventions": [ { "name": "tenofovir + emtricitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 12, "start_date": "2008-10", "completion_date": "2009-05", "has_results": false, "last_update_posted_date": "2012-10-10", "last_synced_at": "2026-10-14T01:24:56.596Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01326221" }, { "nct_id": "NCT00540449", "title": "TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections", "HIV-1", "Human Immunodeficiency Virus Type 1" ], "interventions": [ { "name": "TMC278", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tibotec Pharmaceuticals, Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 694, "start_date": "2008-05", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2016-03-29", "last_synced_at": "2026-10-14T01:24:56.596Z", "location_count": 32, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00540449" }, { "nct_id": "NCT03917420", "title": "Quantification of Estradiol's Impact on Nucleotides in Cellular Populations of the Lower GI Tract", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV/AIDS" ], "interventions": [ { "name": "Tenofovir 300Mg Oral Tablet", "type": "DRUG" }, { "name": "Emtricitabine 200 MG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "FEMALE", "summary": "18 Years to 49 Years · Female only" }, "enrollment_count": 10, "start_date": "2019-03-26", "completion_date": "2019-09-04", "has_results": true, "last_update_posted_date": "2023-04-12", "last_synced_at": "2026-10-14T01:24:56.596Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03917420" }, { "nct_id": "NCT01095796", "title": "Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV", "HIV Infections" ], "interventions": [ { "name": "Stribild", "type": "DRUG" }, { "name": "Atripla", "type": "DRUG" }, { "name": "Stribild Placebo", "type": "DRUG" }, { "name": "Atripla Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 707, "start_date": "2010-03", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2015-11-11", "last_synced_at": "2026-10-14T01:24:56.596Z", "location_count": 97, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 63 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Hayward", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01095796" }, { "nct_id": "NCT03120936", "title": "The Stay Study: A Demonstration Project Advancing PrEP Delivery in the San Francisco Bay Area Transgender Community", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Transgender Persons", "Pre-Exposure Prophylaxis" ], "interventions": [ { "name": "Emtricitabine / Tenofovir Disoproxil Oral Tablet", "type": "DRUG" }, { "name": "PrEP support", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "Public Health Foundation Enterprises, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 158, "start_date": "2017-08-08", "completion_date": "2020-12-01", "has_results": false, "last_update_posted_date": "2021-04-21", "last_synced_at": "2026-10-14T01:24:56.596Z", "location_count": 5, "location_summary": "Fremont, California • San Francisco, California", "locations": [ { "city": "Fremont", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03120936" }, { "nct_id": "NCT01270802", "title": "Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Tenofovir/emtricitabine", "type": "DRUG" }, { "name": "Tenofovir/emtricitabine/efavirenz", "type": "DRUG" }, { "name": "Raltegravir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2011-04", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2013-12-18", "last_synced_at": "2026-10-14T01:24:56.596Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01270802" } ] }